Virologic Failure on Long-Acting CAB/RPV Uncommon but Compromises INSTI Options More Than Doravirine

Among adults with suppressed HIV-1 in France who transitioned to long-acting cabotegravir plus rilpivirine, viral breakthrough rarely occurred.

Yet, whenever resistance did develop, subsequent therapy choices involving dolutegravir or bictegravir were compromised more frequently than those involving doravirine.

That finding emerged from a multicenter cohort study published online on October 14, 2026, in Clinical Infectious Diseases. Researchers at French HIV centers set out to measure how viral breakthrough on injectable antiretroviral therapy impacts susceptibility to subsequent regimens.

The analysis tracked 2,196 adults with a median age of 34 years, of whom 79.2% were men. All participants had achieved viral suppression on oral therapy before transitioning to the injectable combination between 2021 and 2023.

Out of the entire cohort, virologic failure materialized in 42 patients, hitting a median of 103 days after the switch. A striking 90.5% of those failures occurred within the first 12 months, yielding an incidence rate ratio 3.2 times higher in the opening year than afterward.

When resistance mutations surfaced, they disproportionately narrowed options for integrase strand transfer inhibitors. Among 26 patients with failure who underwent genotyping, once-daily dolutegravir or bictegravir remained viable options for 15 individuals according to the French National Agency for Research on AIDS and Viral Hepatitis algorithm, and for 17 individuals under the Stanford HIV Drug Resistance Database algorithm.

By contrast, doravirine retained activity for 24 and 25 patients in those respective evaluations. Emergent resistance-associated mutations cropped up in half of the genotyped group, including atypical patterns tied to low-level viremia.

Multivariate models identified specific baseline characteristics independently linked to a higher risk of treatment failure. A higher body mass index, a lower CD4 nadir, and a shorter duration of prior viral suppression all pushed failure rates upward.

“In cases of confirmed VF, dolutegravir and bictegravir susceptibility may be compromised, whereas doravirine remains largely preserved,” wrote study lead Colin Deschanvres, MD, of Nantes University Hospital in France, and his colleagues.

Several caveats accompanied the observational findings. Differences in clinical practices across multiple sites could have introduced bias, and genotyping data were only available for a subset of failure cases. Extended follow-up past 24 months was scarce, leaving open the question of whether late failures might emerge.

The study received no specific funding. Multiple authors reported financial ties including honoraria and travel support from Gilead Sciences, ViiV Healthcare, and MSD.